DYN
What one share of Dyne Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS.
Dyne Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.34 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.09 |
| Cash and investments | $4.08 |
| Debt | $1.20 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$6.08 | $0.67 | −$5.52 | — | $5.43 |
| 2020 | — | −$4.13 | $0.08 | −$3.31 | — | — |
| 2021 | — | −$2.93 | $0.07 | −$2.42 | — | $7.14 |
| 2022 | — | −$3.23 | $0.06 | −$3.01 | — | $4.54 |
| 2023 | — | −$3.95 | $0.01 | −$3.16 | — | $1.49 |
| 2024 | — | −$3.37 | $0.03 | −$3.13 | — | $6.16 |
| 2025 | — | −$3.47 | $0.01 | −$3.15 | — | $5.89 |